Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 23, Issue 9, 2008, Pages 2868-2872

  Lv, Jicheng ^a   Zhang, Hong ^a   Cui, Zhao ^a   Su, Tao ^a   Zhang, Yimiao ^a   Wang, Haiyan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

IgA nephropathy; Lymphopenia; Mycophenolate mofetil; Pneumocystis pneumonia; Severe pneumonia

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; BRONCHITIS; COHORT ANALYSIS; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DYSFUNCTION; LUNG INFILTRATE; LUNG INSUFFICIENCY; LUNG LAVAGE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RISK FACTOR; SPUTUM ANALYSIS;

ADULT; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PNEUMONIA; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS;

EID: 58549087361     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn161     Document Type: Article

References (27)

1. Gabriel M. Danovitch: mycophenolate mofetil: a decade of clinical experience. Tansplantation 2005; 80: S72-S73
2. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84
3. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80: S191-S200
4. APCPel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Tansplantation 2005; 80: S265-S271
5. Chan TM, Li FK, Tang CS et al. Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162
6. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980
7. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084
8. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolat mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
9. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510
10. Branten AJ, du Buf-Vereijken PW, Vervloet M et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50: 248-256
11. Zhao M, Chen X, Chen Y et al. Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology (Carlton) 2003; 8: 105-109
12. Azevedo LS, Castro MCR, Paula FJ et al. Mycophenolate Mofetil may protect against pneumocystis carinii pneumonia in renal transplanted patients. Rev Inst Med Trop Sao Paulo 2005; 47: 143-145
13. Oz HS, Hughes WT. Novel anti-pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175: 901-904
14. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35: 53-61
15. Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
16. Ma YC, Zuo L, Chen JH et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2937-2944
17. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of pneumocystis pneumonia. Nat Rev Microbiol 2007; 5: 298-308
18. Wenzel RP, Fowler AA III. Clinical practice. Acute bronchitis. N Engl J Med 2006; 16: 2125-2130
19. Iaccarino L, Rampudda M, Canova M et al. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic disease. Autoimmun Rev 2007; 6: 190-195
20. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942
21. Totet A, Westeel PF, Nevez G. Severe pneumocystis pneumonia in a renal transplant recipient after long term mycophenolate mofetil treatment. Rev Inst Med Trop Sao Paulo 2005; 47: 303-304.
22. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849
23. Frisch G, Lin J, Rosenstock J et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139-2145
24. Tang S, Leung JCK, Chan LYYet al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 86: 802-812
25. Chen X, Chen P, Cai G et al. A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi 2002; 82: 796-801
26. MacPhee IA, Spreafico S, Bewick M et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000; 57: 1164-1168
27. González-Roncero FM, Gentil MA, Brunet M et al. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc 2005; 37: 3749-3751